抗血小板和抗凝剂在玻璃结膜外科手术:一个系统的审查
Filippo Confalonieri1,2,3,4, Vanessa Ferraro1,2, Alessandra Di Maria1,2
1Department of Ophthalmology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
Life (Basel, Switzerland)
|June 28, 2023
概括
抗血小板药物和抗凝血剂在玻璃视网膜外科手术中有益,尽管存在潜在的出血风险. 证据表明,它们的优点超过了患者结果的缺点.
科学领域:
- 眼科医生 眼科 眼科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血小板和抗凝血药物显著影响玻璃甲状腺外科手术.
- 较新的口服抗凝剂需要更新临床指南,用于外科手术期间的管理.
- 外科医生需要基于证据的数据来管理这些药物在玻璃视网膜手术过程中.
研究的目的:
- 在外科手术期间对抗血小板和抗凝剂的使用进行系统审查.
- 评估相关并发症和证据水平,以管理这些药物.
主要方法:
- 按照PRISMA指南进行系统审查.
- 使用牛津证据医学中心 (OCEM) 评估证据水平 2011.
- 使用推评估,开发和评估 (GRADE) 的评级来评估证据质量.
主要成果:
- 最初的搜索产生了2310篇文章;22篇在选后符合纳入标准.
- 分析的重点是围绕手术期间使用的抗血小板和抗凝剂在玻璃甲状腺外科手术中.
- 术后出血并发症被确定为主要问题.
结论:
- 有限的高质量研究存在,但目前的证据支持继续使用抗血小板/抗凝剂.
- 这些药物的益处在玻璃视网膜外科手术中似乎超过了风险.
- 需要进一步的研究来巩固基于证据的指导方针.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
567
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
567
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763


